OBJECTIVE: The aim of the study was to examine whether comorbidity is an independent prognostic factor for 3129 women diagnosed with ovarian cancer from 2005 to 2011. As Performance status (PS) might capture the impact of comorbidity we addressed whether comorbidity can be explained by PS or whether comorbidity has an independent impact on survival. METHODS: The Danish Gynecological Cancer Database (DGCD) is a national clinical database including information on comorbidity and a large number of tumor-related and patient-related factors. The Charlson Comorbidity Index was used to measure the patients' comorbidity based on the registration in DGCD. The overall mortality (OS) from the date of surgery to death or censoring was the outcome measure. RESULTS: The hazard ratio (HR) for patients with comorbidity was 3.31 (1.14-1.50) compared to patients without comorbidity after adjustment for age, stage, residual tumor, histology and grade. After including PS in the model, comorbidity remained significant for OS. Age, stage, residual tumor, histology and PS prove to be independent prognostic factors as well. No association is found between comorbidity and receiving surgery or not. CONCLUSION: Comorbidity is an independent prognostic factor, and has a negative impact on the survival of ovarian cancer patients. However, comorbidity has a smaller impact on survival compared with the other prognostic factors considered.
OBJECTIVE: The aim of the study was to examine whether comorbidity is an independent prognostic factor for 3129 women diagnosed with ovarian cancer from 2005 to 2011. As Performance status (PS) might capture the impact of comorbidity we addressed whether comorbidity can be explained by PS or whether comorbidity has an independent impact on survival. METHODS: The Danish Gynecological Cancer Database (DGCD) is a national clinical database including information on comorbidity and a large number of tumor-related and patient-related factors. The Charlson Comorbidity Index was used to measure the patients' comorbidity based on the registration in DGCD. The overall mortality (OS) from the date of surgery to death or censoring was the outcome measure. RESULTS: The hazard ratio (HR) for patients with comorbidity was 3.31 (1.14-1.50) compared to patients without comorbidity after adjustment for age, stage, residual tumor, histology and grade. After including PS in the model, comorbidity remained significant for OS. Age, stage, residual tumor, histology and PS prove to be independent prognostic factors as well. No association is found between comorbidity and receiving surgery or not. CONCLUSION: Comorbidity is an independent prognostic factor, and has a negative impact on the survival of ovarian cancerpatients. However, comorbidity has a smaller impact on survival compared with the other prognostic factors considered.
Authors: Rudy S Suidan; Mario M Leitao; Oliver Zivanovic; Ginger J Gardner; Kara C Long Roche; Yukio Sonoda; Douglas A Levine; Elizabeth L Jewell; Carol L Brown; Nadeem R Abu-Rustum; Mary E Charlson; Dennis S Chi Journal: Gynecol Oncol Date: 2015-05-31 Impact factor: 5.482
Authors: Camilla Praestegaard; Allan Jensen; Signe M Jensen; Thor S S Nielsen; Penelope M Webb; Christina M Nagle; Anna DeFazio; Estrid Høgdall; Mary Anne Rossing; Jennifer A Doherty; Kristine G Wicklund; Marc T Goodman; Francesmary Modugno; Kirsten Moysich; Roberta B Ness; Robert Edwards; Keitaro Matsuo; Satoyo Hosono; Ellen L Goode; Stacey J Winham; Brooke L Fridley; Daniel W Cramer; Kathryn L Terry; Joellen M Schildkraut; Andrew Berchuck; Elisa V Bandera; Lisa E Paddock; Leon F Massuger; Nicolas Wentzensen; Paul Pharoah; Honglin Song; Alice Whittemore; Valerie McGuire; Weiva Sieh; Joseph Rothstein; Hoda Anton-Culver; Argyrios Ziogas; Usha Menon; Simon A Gayther; Susan J Ramus; Alexandra Gentry-Maharaj; Anna H Wu; Celeste L Pearce; Malcolm Pike; Alice W Lee; Rebecca Sutphen; Jenny Chang-Claude; Harvey A Risch; Susanne K Kjaer Journal: Int J Cancer Date: 2017-01-24 Impact factor: 7.396
Authors: Zhaomin Xu; Adan Z Becerra; Carla F Justiniano; Christopher T Aquina; Fergal J Fleming; Francis P Boscoe; Maria J Schymura; Abdulrahman K Sinno; Jessica Chaoul; Gary R Morrow; Lori Minasian; Sarah M Temkin Journal: J Surg Res Date: 2019-09-24 Impact factor: 2.192
Authors: Albina N Minlikeeva; Jo L Freudenheim; Rikki A Cannioto; J Brian Szender; Kevin H Eng; Francesmary Modugno; Roberta B Ness; Michael J LaMonte; Grace Friel; Brahm H Segal; Kunle Odunsi; Paul Mayor; Emese Zsiros; Barbara Schmalfeldt; Rüdiger Klapdor; Thilo Dӧrk; Peter Hillemanns; Linda E Kelemen; Martin Kӧbel; Helen Steed; Anna de Fazio; Susan J Jordan; Christina M Nagle; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Robert Edwards; Keitaro Matsuo; Mika Mizuno; Beth Y Karlan; Susanne K Kjær; Estrid Høgdall; Allan Jensen; Joellen M Schildkraut; Kathryn L Terry; Daniel W Cramer; Elisa V Bandera; Lisa E Paddock; Lambertus A Kiemeney; Leon F Massuger; Jolanta Kupryjanczyk; Andrew Berchuck; Jenny Chang-Claude; Brenda Diergaarde; Penelope M Webb; Kirsten B Moysich Journal: Cancer Causes Control Date: 2017-03-14 Impact factor: 2.506
Authors: Lise Vilstrup Holm; Dorte Gilså Hansen; Jakob Kragstrup; Christoffer Johansen; Rene dePont Christensen; Peter Vedsted; Jens Søndergaard Journal: Support Care Cancer Date: 2014-03-19 Impact factor: 3.603
Authors: Nadia Yousaf; Samuel Harris; Juan Martin-Liberal; Susannah Stanway; Mark Linch; Maria Ifijen; Omar Al Muderis; Komel Khabra; Cyril Fisher; Jonathan Noujaim; Ian Judson; Charlotte Benson Journal: Clin Sarcoma Res Date: 2015-03-24
Authors: Albina N Minlikeeva; Jo L Freudenheim; Kevin H Eng; Rikki A Cannioto; Grace Friel; J Brian Szender; Brahm Segal; Kunle Odunsi; Paul Mayor; Brenda Diergaarde; Emese Zsiros; Linda E Kelemen; Martin Köbel; Helen Steed; Anna deFazio; Susan J Jordan; Peter A Fasching; Matthias W Beckmann; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Jenny Chang-Claude; Marc T Goodman; Thilo Dörk; Robert Edwards; Francesmary Modugno; Roberta B Ness; Keitaro Matsuo; Mika Mizuno; Beth Y Karlan; Ellen L Goode; Susanne K Kjær; Estrid Høgdall; Joellen M Schildkraut; Kathryn L Terry; Daniel W Cramer; Elisa V Bandera; Lisa E Paddock; Lambertus A Kiemeney; Leon F A G Massuger; Rebecca Sutphen; Hoda Anton-Culver; Argyrios Ziogas; Usha Menon; Simon A Gayther; Susan J Ramus; Aleksandra Gentry-Maharaj; Celeste L Pearce; Anna H Wu; Jolanta Kupryjanczyk; Allan Jensen; Penelope M Webb; Kirsten B Moysich Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-09 Impact factor: 4.090